Author pages are created from data sourced from our academic publisher partnerships and public sources.
Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and…
PURPOSE To evaluate the efficacy and ocular and systemic safety of netarsudil 0.02% ophthalmic solution, a rho-kinase inhibitor and norepinephrine transporter inhibitor, in patients with open-angle… Expand
Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: 3-Month Data From a Randomized Phase 3 Trial.
PURPOSE To compare the ocular hypotensive efficacy and safety of a fixed-dose combination (FDC) of the Rho kinase inhibitor netarsudil and latanoprost vs monotherapy with netarsudil or latanoprost.… Expand
Effect of 0.04% AR-13324, a ROCK, and Norepinephrine Transporter Inhibitor, on Aqueous Humor Dynamics in Normotensive Monkey Eyes
- Rongfang Wang, Jennifer E. Williamson, C. Kopczynski, Janet B. Serle
- Journal of glaucoma
- 1 January 2015
Purpose:To determine the mechanism by which topically applied AR-13324, a rho kinase inhibitor, and an inhibitor of the norepinephrine transporter, reduces intraocular pressure (IOP) in normotensive… Expand
Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure.
OBJECTIVE AR-13324 is a small-molecule inhibitor of Rho kinase and a norepinephrine transporter. The objective of this 28-day study was to evaluate the ocular hypotensive efficacy and safety of… Expand
Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma
- Cheng-wen Lin, B. Sherman, +6 authors C. Kopczynski
- Biology, Medicine
- Journal of ocular pharmacology and therapeutics…
- 13 June 2017
Abstract Purpose: Rho-associated protein kinase (ROCK) inhibitors lower intraocular pressure (IOP) by increasing aqueous outflow through the trabecular meshwork (TM). The preclinical characterization… Expand
Role of the Rho GTPase/Rho kinase signaling pathway in pathogenesis and treatment of glaucoma: Bench to bedside research
ABSTRACT Glaucoma is a leading cause of irreversible blindness worldwide. Elevated intraocular pressure (IOP) is considered to be a predominant risk factor for primary open angle glaucoma, the most… Expand
Consensus recommendations for trabecular meshwork cell isolation, characterization and culture.
Cultured trabecular meshwork (TM) cells are a valuable model system to study the cellular mechanisms involved in the regulation of conventional outflow resistance and thus intraocular pressure; and… Expand
Once-Daily Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure in the Randomized Phase 3 MERCURY-2 Study.
PURPOSE To compare the ocular hypotensive efficacy and safety of a once-daily (pm) fixed-dose combination (FDC) product containing netarsudil 0.02% and latanoprost 0.005% with monotherapy with… Expand
Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension.
- R. Williams, G. Novack, Thomas van Haarlem, C. Kopczynski
- American journal of ophthalmology
- 1 November 2011
PURPOSE To evaluate the ocular hypotensive efficacy of 0.05%, 0.1% and 0.25% AR-12286 Ophthalmic Solutions in patients diagnosed with ocular hypertension or glaucoma. DESIGN Parallel comparison,… Expand
Emerging trabecular outflow drugs.
Glaucoma is a progressive optic neuropathy that is a leading cause of irreversible blindness worldwide.1 Elevated intraocular pressure (IOP) is commonly associated with glaucoma, and multiple… Expand